mdlinx mdlinx
Latest (26) Full Text Articles (989) Focus on Dialysis Article Summary

Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy Full Text
Journal of the American Society of Nephrology,  Clinical Article

Kohan DE et al. - Atrasentan, at the doses tested i.e. 0.25, 0.75, or 1.75 mg daily, is generally safe and effective in reducing residual albuminuria and may ultimately improve renal outcomes in patients with type 2 diabetic nephropathy.

Methods
  • Authors examined the effect of atrasentan, a selective endothelin A receptor (ETAR) antagonist, on albuminuria.
  • This is a randomized, double-blind, placebo-controlled trial of subjects with diabetic nephropathy already receiving stable doses of renin-angiotensin system (RAS) inhibitors.
  • 89 subjects with eGFR >20 ml/min per 1.73 m2 and a urinary albumin-to-creatinine ratio (UACR) of 100 to 3000 mg/g to placebo or atrasentan (0.25, 0.75, or 1.75 mg daily) for 8 weeks were assigned.

Results
  • Compared with placebo, atrasentan significantly reduced urinary albumin-to-creatinine ratio (UACR) only in the 0.75- and 1.75-mg groups (P = 0.001 and P = 0.011, respectively).
  • Compared with the 11% reduction in the geometric mean of the UACR from baseline to final observation in the placebo group during the study, the geometric mean of UACR decreased by 21, 42, and 35% in the 0.25-, 0.75-, and 1.75-mg atrasentan groups (P = 0.291, P = 0.023, and P = 0.073, respectively).
  • In the placebo group, 17% of subjects achieved >=40% reduction in UACR from baseline compared with 30, 50, and 38% in the 0.25-, 0.75-, and 1.75-mg atrasentan groups, respectively (P = 0.029 for 0.75 mg versus placebo).
  • Peripheral edema occurred in 9% of subjects receiving placebo and in 14, 18, and 46% of those receiving 0.25, 0.5, and 1.75 mg atrasentan, respectively (P = 0.007 for 1.75 mg versus placebo).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Nephrology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Nephrology Articles

Last month's top read Top Articles of 2013

Indexed Journals in Nephrology: Kidney International, Hemodialysis International, Nephrology Dialysis Transplantationmore

Other Topics in Nephrology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close